Creatine Supplementation and Resistance Training in Patients With Breast Cancer

Breast Cancer Clinical Trial

— CaRTiC  

Official title:

Creatine Supplementation and Resistance Training in Patients With Breast Cancer (CaRTiC Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05878106
• Other study ID #: CaRTiC
• Status: Recruiting
• Phase: N/A
• Start date: April 8, 2024
• Est. completion date: December 8, 2025

Study information

• Verified date: May 2024
• Source: University of Deusto
• Contact: Arkaitz Castañeda, PhD
• Phone: 944139003
• Email: arkaitz.castaneda[@]deusto.es
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Creatine supplementation is an effective ergogenic nutrient for athletes, as well as people for people starting a health or fitness program. Resistance training previously been identified as an important method of increasing muscle mass and strength among people, specially in people with cancer to avoid sarcopenia. The potential of creatine supplementation for adaptations produced by strength training in cancer patients are still unknown.

Objective: the primary aim of this study is to evaluate the effectiveness of a 16-week supervised resistance training program intervention with and without creatine supplementation in patients with breast cancer.

Methods: A multicentre, randomized, double-blind, placebo-controlled study designed to evaluate the effects of creatine supplementation in addition to resistance training in breast cancer patients. Patients will be randomly assigned to 3 groups: a control group (CG) and two experimental groups. The first resistance training group (RG) will perform resistance training, while the second resistance-creatine experimental group (RCG) will perform the same resistance training as the RG and will also receive a 5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention. RG participants will follow the same daily dosing protocol, but in their case, with dextrose/maltodextrin. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days. Both the RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily.

Discussion: The results of this intervention will help to better understand the potential of non-pharmacological treatment for improving strength and wellbeing values in breast cancer patients with and without creatine supplementation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 8, 2025
• Est. primary completion date: April 20, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Stage pTis-T1-T2-T3 pN0-1 M0 (early stage).

• Patients who have completed local treatment [surgery + radiotherapy (RT)] undergoing clinical follow-up in outpatient clinics with or without adjuvant hormone therapy treatment.

• Age: =18-60 years.

• ECOG Performance status from 0 to 1 (IK =80%).

• Body mass index above than 18.5.

• Without excessive alcohol consumption (men > 21 and women > 14 units/week).

• No current or previous illness or injury that may prevent participation and training.

• No recent systematic strength training.

• Not taking medications that are known to alter body composition (corticosteroids, metformin...).

• People who carry out some aerobic training will not be excluded (the activity carried out will be recorded weekly).

Exclusion Criteria:

• Having received adjuvant or neoadjuvant chemotherapy.

• Metastatic carcinoma of the breast.

• Recurrence or second primary breast.

• History of previous cancer except previously treated basal cell carcinoma of the skin.

• Decompensated heart disease, uncontrolled hypertension (TAS>200 or TAD>110), heart failure (NYHA II or greater), heart failure or constrictive pericarditis, neutropenia, severe anemia (Hb<8.0 g/dl), blood count platelets <50,000 microL.

• Other health problems in which exercise is contraindicated

• Perform regular physical activity (150 min/week of moderate activity or 75 of vigorous activity), measured with the PVS questionnaire.

• Pregnancy.

• Criterion in the opinion of the investigator of inability to adequately understand the involvement and participation in this clinical study.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Physical Performance
• Quality of Life
• Resistance Training
• Supplementation

Intervention

Dietary Supplement:
• Creatine supplementation
5 g/day supplementation of creatine for the duration of the exercise the 16-week intervention. The RG and the RCG will receive a supplement of soluble protein powder (20-30 g) daily.

Other:
• Resistance training
They will do resistance training. Resistance training will be a 16-week supervised workout that will consist of a series of resistance exercises (leg press, knee extension, knee bends, chest press, sit-ups, back extensions, pull-ups, and shoulder press) that involved the largest muscle groups of the body and will be performed three times a week on non-consecutive days.

Locations

Country	Name	City	State
Spain	Hospital de Cruces	Bilbao	Bizkaia

Sponsors (6)

Lead Sponsor	Collaborator
University of Deusto	Hospital de Basurto, Hospital de Cruces, Hospital Universitario de Burgos, Poznan University of Medical Sciences, University of Calabria

Country where clinical trial is conducted

Spain, 

References & Publications (33)

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365. — View Citation

Boidin M, Dawson EA, Thijssen DHJ, Erskine RM. VEGFA rs2010963 GG genotype is associated with superior adaptations to resistance versus endurance training in the same group of healthy, young men. Mol Genet Genomics. 2023 Jan;298(1):119-129. doi: 10.1007/s00438-022-01965-4. Epub 2022 Nov 3. — View Citation

Brosnan ME, Brosnan JT. The role of dietary creatine. Amino Acids. 2016 Aug;48(8):1785-91. doi: 10.1007/s00726-016-2188-1. Epub 2016 Feb 13. — View Citation

Buford TW, Kreider RB, Stout JR, Greenwood M, Campbell B, Spano M, Ziegenfuss T, Lopez H, Landis J, Antonio J. International Society of Sports Nutrition position stand: creatine supplementation and exercise. J Int Soc Sports Nutr. 2007 Aug 30;4:6. doi: 10.1186/1550-2783-4-6. No abstract available. — View Citation

Campos-Ferraz PL, Gualano B, das Neves W, Andrade IT, Hangai I, Pereira RT, Bezerra RN, Deminice R, Seelaender M, Lancha AH. Exploratory studies of the potential anti-cancer effects of creatine. Amino Acids. 2016 Aug;48(8):1993-2001. doi: 10.1007/s00726-016-2180-9. Epub 2016 Feb 12. — View Citation

Candow DG, Forbes SC, Chilibeck PD, Cornish SM, Antonio J, Kreider RB. Effectiveness of Creatine Supplementation on Aging Muscle and Bone: Focus on Falls Prevention and Inflammation. J Clin Med. 2019 Apr 11;8(4):488. doi: 10.3390/jcm8040488. — View Citation

Cella D, Nowinski CJ. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002 Dec;83(12 Suppl 2):S10-7. doi: 10.1053/apmr.2002.36959. — View Citation

Chandrashekhar Iyer L, Vaishali K, Babu AS. Prevalence of sarcopenia in heart failure: A systematic review. Indian Heart J. 2023 Jan-Feb;75(1):36-42. doi: 10.1016/j.ihj.2022.12.004. Epub 2022 Dec 22. — View Citation

Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J Cell Biol. 2010 Sep 6;190(5):867-79. doi: 10.1083/jcb.200911036. — View Citation

Cornelissen VA, Defoor JG, Stevens A, Schepers D, Hespel P, Decramer M, Mortelmans L, Dobbels F, Vanhaecke J, Fagard RH, Vanhees L. Effect of creatine supplementation as a potential adjuvant therapy to exercise training in cardiac patients: a randomized controlled trial. Clin Rehabil. 2010 Nov;24(11):988-99. doi: 10.1177/0269215510367995. Epub 2010 Jun 24. — View Citation

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum In: Age Ageing. 2019 Jul 1;48(4):601. — View Citation

Dolan E, Artioli GG, Pereira RMR, Gualano B. Muscular Atrophy and Sarcopenia in the Elderly: Is There a Role for Creatine Supplementation? Biomolecules. 2019 Oct 23;9(11):642. doi: 10.3390/biom9110642. — View Citation

Erskine RM, Williams AG, Jones DA, Stewart CE, Degens H. The individual and combined influence of ACE and ACTN3 genotypes on muscle phenotypes before and after strength training. Scand J Med Sci Sports. 2014 Aug;24(4):642-8. doi: 10.1111/sms.12055. Epub 2013 Feb 5. — View Citation

Fairman CM, Kendall KL, Newton RU, Hart NH, Taaffe DR, Chee R, Tang CI, Galvao DA. Examining the effects of creatine supplementation in augmenting adaptations to resistance training in patients with prostate cancer undergoing androgen deprivation therapy: a randomised, double-blind, placebo-controlled trial. BMJ Open. 2019 Sep 20;9(9):e030080. doi: 10.1136/bmjopen-2019-030080. — View Citation

Fenech M, El-Sohemy A, Cahill L, Ferguson LR, French TA, Tai ES, Milner J, Koh WP, Xie L, Zucker M, Buckley M, Cosgrove L, Lockett T, Fung KY, Head R. Nutrigenetics and nutrigenomics: viewpoints on the current status and applications in nutrition research and practice. J Nutrigenet Nutrigenomics. 2011;4(2):69-89. doi: 10.1159/000327772. Epub 2011 May 28. — View Citation

Gerland L, Baumann FT, Niels T. Resistance Exercise for Breast Cancer Patients? Evidence from the Last Decade. Breast Care (Basel). 2021 Dec;16(6):657-663. doi: 10.1159/000513129. Epub 2021 Jan 28. — View Citation

Giallauria F, Cittadini A, Smart NA, Vigorito C. Resistance training and sarcopenia. Monaldi Arch Chest Dis. 2016 Jun 22;84(1-2):738. doi: 10.4081/monaldi.2015.738. — View Citation

Hall M, Trojian TH. Creatine supplementation. Curr Sports Med Rep. 2013 Jul-Aug;12(4):240-4. doi: 10.1249/JSR.0b013e31829cdff2. — View Citation

Hardee JP, Porter RR, Sui X, Archer E, Lee IM, Lavie CJ, Blair SN. The effect of resistance exercise on all-cause mortality in cancer survivors. Mayo Clin Proc. 2014 Aug;89(8):1108-15. doi: 10.1016/j.mayocp.2014.03.018. Epub 2014 Jun 21. — View Citation

Iannone F, Montesanto A, Cione E, Crocco P, Caroleo MC, Dato S, Rose G, Passarino G. Expression Patterns of Muscle-Specific miR-133b and miR-206 Correlate with Nutritional Status and Sarcopenia. Nutrients. 2020 Jan 22;12(2):297. doi: 10.3390/nu12020297. — View Citation

Kim HJ, Kim CK, Carpentier A, Poortmans JR. Studies on the safety of creatine supplementation. Amino Acids. 2011 May;40(5):1409-18. doi: 10.1007/s00726-011-0878-2. Epub 2011 Mar 12. — View Citation

Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017. — View Citation

Kreider RB, Stout JR. Creatine in Health and Disease. Nutrients. 2021 Jan 29;13(2):447. doi: 10.3390/nu13020447. — View Citation

Lonbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients--the DAHANCA 25A study. Acta Oncol. 2013 Feb;52(2):310-8. doi: 10.3109/0284186X.2012.741325. Epub 2012 Nov 28. — View Citation

Norman K, Stubler D, Baier P, Schutz T, Ocran K, Holm E, Lochs H, Pirlich M. Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer--a double blind randomised controlled trial. Clin Nutr. 2006 Aug;25(4):596-605. doi: 10.1016/j.clnu.2006.01.014. Epub 2006 May 15. — View Citation

Padilha CS, Marinello PC, Galvao DA, Newton RU, Borges FH, Frajacomo F, Deminice R. Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis. J Cancer Surviv. 2017 Jun;11(3):339-349. doi: 10.1007/s11764-016-0592-x. Epub 2017 Jan 4. — View Citation

Patra S, Ghosh A, Roy SS, Bera S, Das M, Talukdar D, Ray S, Wallimann T, Ray M. A short review on creatine-creatine kinase system in relation to cancer and some experimental results on creatine as adjuvant in cancer therapy. Amino Acids. 2012 Jun;42(6):2319-30. doi: 10.1007/s00726-011-0974-3. Epub 2011 Jul 19. — View Citation

Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller RF, Devaney JM, Hoffman EP. ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc. 2006 Jun;38(6):1074-81. doi: 10.1249/01.mss.0000222835.28273.80. — View Citation

Pinheiro PA, Carneiro JA, Coqueiro RS, Pereira R, Fernandes MH. "Chair Stand Test" as Simple Tool for Sarcopenia Screening in Elderly Women. J Nutr Health Aging. 2016 Jan;20(1):56-9. doi: 10.1007/s12603-016-0676-3. — View Citation

Soares RJ, Cagnin S, Chemello F, Silvestrin M, Musaro A, De Pitta C, Lanfranchi G, Sandri M. Involvement of microRNAs in the regulation of muscle wasting during catabolic conditions. J Biol Chem. 2014 Aug 8;289(32):21909-25. doi: 10.1074/jbc.M114.561845. Epub 2014 Jun 2. — View Citation

Stares A, Bains M. The Additive Effects of Creatine Supplementation and Exercise Training in an Aging Population: A Systematic Review of Randomized Controlled Trials. J Geriatr Phys Ther. 2020 Apr/Jun;43(2):99-112. doi: 10.1519/JPT.0000000000000222. — View Citation

Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83. — View Citation

Zhang G, Li X, Sui C, Zhao H, Zhao J, Hou Y, DU Y. Incidence and risk factor analysis for sarcopenia in patients with cancer. Oncol Lett. 2016 Feb;11(2):1230-1234. doi: 10.3892/ol.2015.4019. Epub 2015 Dec 9. — View Citation

* Note: There are 33 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in maximal resistance (upper and lower body)	The maximal resistance in the upper and lower body will be measured in terms of the 5-repetition maximum test (5RM) (i.e. the maximum load that can be lifted five times) in chest and leg press exercises, respectively. Also a handgrip dynamometry test will be used to measure grip resistance.	7 months follow up. Measures at 0, 2, 4 and 7 months.
Primary	Genetic study	Saliva samples will be taken from the participants using buccal swabs (4N6FLOQSwab, Life Technologies, Carlsbad, CA). The genetic analysis will be performed using Biomark HD system microfluidic analysis technology (Fluidigm, South San Francisco, CA). From that analysis DNA will be extracted using the QIAmp DNA Mini kit (Qiagen, Hilden, Germany) and will be quantified fluorometrically using Qubit (LifeTechnologies).	Month 0
Primary	Change in Micro RNA (mRNA)	A 5/10 ml of urine will be collected in a 15 ml sterile plastic universal container tube kept at room temperature no more than 60 minutes, then stored at -20°C. Total RNA will be extracted from 400 µl of urine by using miRNeasy Serum/Plasma Kit (QIAGEN).	Month 0 and 4
Secondary	Change in Physical function (walking)	Physical function is assessed by the 6 Minute Walk Test (6MWT) in a 20-meter corridor. Is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in Physical function (sitting)	A 30-s chair test will be performed performed to measure functional capacity. The number of stands a person can complete in 30 seconds will be recorded.	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in Body composition	Body composition (percentages of type of tissue) will be measured using a bioelectrical impedance analysis (Inbody 770, In-Bldg).	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in dietary pattern	Habitual food consumption and nutrient intake will be evaluated using the dietary history questionnaire.	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in Gastrointestinal discomfort	The unidimensional Gastrointestinal Function questionnaire was used to assess gastrointestinal discomfort. This questionnaire consists of 9 items with a frequency scale of 4 response options [none (0 points), mild (1 point), moderate (2 points) and severe (3 points)].	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in Quality of life (general)	The Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) is used to assess general health-related quality of life status across physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning, and mental health domains (higher scores indicating a greater quality of life). with scores for each of these scales (or dimensions) ranging from 0 to 100. Higher scores indicate higher quality of life.	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in Quality of life (cancer specific)	Cancer-specific quality of life is evaluated by the core quality of life (QLQ-C-30) questionnaire developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire includes five functional domains (physical, role, cognitive, emotional, and social, with higher scores representing greater function/quality of life) and three symptom scales (fatigue, pain, and nausea, with lower scores indicating greater quality of life/less symptom severity).	7 months follow up. Measures at 0, 2, 4 and 7 months.
Secondary	Change in fatigue level	The cancer-related fatigue is assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale. For all FACIT scales and symptom indices, the higher the score the better the quality of life.	7 months follow up. Measures at 0, 2, 4 and 7 months.